Healthcare
Photocure ASA(PHCUF)
Live Price
Offline$6.18
+0.00% today
1Y Change
+19.08%
Window
Jun 23, 2025 โ Jun 15, 2026
- Market Cap
- $1.75B
- Revenue Growth
- +1.3%
- EPS Growth
- +68.1%
- Dividend Yield
- 0.0%
Coverage: 252 bars ยท Jun 23, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Photocure ASA (PHCUF) is a Healthcare stock with a market cap of $1.75B and listed on OTC. The stock last traded around $6.18 and up 19.1% across the available one-year price window (Jun 23, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of +1.3%, EPS growth of +68.1%, a dividend yield of 0.0%. What stands out right now is revenue +1.3%, EPS +68.1%, free cash flow -42.4% with operating margin 10.2% and ROIC 0.8%. Valuation is more restrained than many high-expectation growth names at price/sales 3.3. Stock Foundry combines PHCUF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+1.3% vs +7.6% peer median
Operating Margin
Below sector median
+10.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +1.3% and EPS at +68.1%, with operating margin around 10.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1.5% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | โ | +0.0% | +4.5% | -12.0% |
2026 Feb 18, 2026 | -3.4% | +0.0% | +0.0% | +1.0% |
2025 Jul 30, 2025 | +780.3% | +0.0% | +0.0% | -2.1% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PHCUF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PHCUF Max Drawdown
-16.37%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PHCUF and SPY.
Company Overview
Photocure ASA
Other OTC
Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the Netherlands, Italy, other European Countries, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.
- Leadership
- Daniel Schneider
- IPO Date
- Sep 24, 2013
- Employees
- 99
- Street Address
- Hoffsveien 4
- Mailing
- Oslo, 0275
- Region
- Oslo, NO
- Reporting Currency
- USD
- Investor Line
- 47 22 06 22 10
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 21.3
- Price/Sales
- 3.3
- Price/Book
- 3.6
Growth
- Revenue
- +1.3%
- EPS
- +68.1%
- Free Cash Flow
- -42.4%
Profitability
- Gross Margin
- 90.7%
- Operating Margin
- 10.2%
- Net Margin
- -0.3%
- ROE
- -0.3%
- ROIC
- 0.8%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 3.64
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.